Author

Isabelle Willoughby

University of Washington

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:cryo-EM· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Cameron StewartiD· 2 shared Catherine TreicheliD· 2 shared David VeesleriD· 2 shared Elizabeth M. LeafiD· 2 shared Jack T BrowniD· 2 shared Jimin LeeiD· 2 shared Neil P. KingiD· 2 shared Adian Valdez· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Cameron StewartORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines

Amin Addetia, Alexandra Schäfer, Kaitlin R. Sprouse, Adian Valdez, Ashley Taylor, Mary-Jane Navarro, Jack T Brown, Elizabeth M. Leaf, Marcos C. Miranda, Alexandra C. Walls, Jimin Lee, Nicholas Catanzaro, Catherine Treichel, Isabelle Willoughby, John Powers, , David Veesler

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

bioRxiv · May 11, 2025 · PreprintImmunology

Molecular basis of pathogenicity of the recently emerged FCoV-23 coronavirus

M. Alejandra Tortorici, Annette Choi, Cecily A. Gibson, Jimin Lee, Jack T Brown, Cameron Stewart, Anshu Joshi, Sheri Harari, Isabelle Willoughby, Catherine Treichel, Elizabeth M. Leaf, Jesse D. Bloom, Neil P. King, Christine Tait‐Burkard, Gary R. Whittaker, David Veesler

This study identifies molecular mechanisms of FCoV-23 pathogenicity, including receptor usage and biotype switching, and identifies a cross-reactive antibody for therapeutic development.

bioRxiv · Aug 25, 2024 · PreprintBiochemistry